ResearcherInsermNo recent work listed
Gaëlle Thomas
Matched on OpenAlex author ID A5084302879. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper
Papers 3
- Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Co-author DOI 10.1016/j.canlet.2018.06.023↗
- Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Co-author DOI 10.1038/onc.2013.487↗
- HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Co-author DOI 10.18632/oncotarget.2231↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christel Larbouret · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- André Pèlegrin · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Thierry Chardès · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Bruno Robert · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Pierre‐Emmanuel Colombo · 2 shared papers, 2014–2018 · strength 0.10
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Wilhem Leconet · 2 shared papers, 2014 · strength 0.07
- Corinne Bousquet · 1 shared paper, 2018 · strength 0.06
- Charline Ogier · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.